Pneumotox. vs CareCentral

Pneumotox®: The drug-induced/iatrogenic respiratory disease website & App. The companion website and App Cardiotox® cover drug-induced cardiotoxicity. By Philippe Camus MD. Professor (emeritus) - Board-certified in pulmonary medicine and cardiology,- Université Bourgone-Europe, Dijon, France. Pneumotox is an aid to the diagnosis and management of respiratory diseases and reactions suspected of being induced by drugs, chemicals, and of iatrogenic origin. Causality assessment and exact diagnosis are the full responsibility of the user. Pneumotox is designed to provide regularly-updated information on drugs causing pulmonary toxicity (>1,700 agents), patterns of involvement (>820) and bibliography (>10,700 as of August 2026) within a few minutes. That may be the crux in emergency situations. Yet, double-checking in and from other sources is indicated. Pneumotox rests on a bibliographic repository built since 1978, which amounts to >50,000 references overall, the vast majority of which is indexed in PubMed. All references were and are carefully reviewed for reliability and causality by the founder, then indexed under the corresponding drug or agent in Pneumotox. Pneumotox can be assessed by causative drug(s), chemicals, herbals, substances of abuse, inhaled incl. e-cigarettes, vaping, inhalants, gases, ionizing radiations (providing the list of patterns), or by patterns of involvement (providing the list of causal drugs/agents). Drug names are generic (International Nonproprietary Names (INN), alphabetical), not brand ones. It may be appropriate to check the exact composition of any proprietary drug, as any other added substance or excipient can be pneumotoxic. Matching generic and brand names which differs with country is the responsibility of the user. Patterns are grouped by families according to the main anatomic site of involvement. If a drug or drug reaction is listed in Pneumotox, that does not equate the patient is demonstrating toxicity. A “Diagnosing DIRD” window in Pneumotox (top panel) may help secure the diagnosis. Lack of case or cases in the literature or in Pneumotox does not exclude a diagnosis of drug toxicity as there may be unpublished cases, you may be seeing the first case ever, or we may have overlooked some information. In such situations, please inform us; Pneumotox cannot be held responsible. Pneumotox can be contacted by mail 7/365 for complementary information, tailored literature, and/or data on rechallenge with the drug. In any patient, particularly the ones with acute respiratory failure, ARDS or acute bronchospasm, exposure to drugs, substances, and/or chemicals must be done exhaustively with the patient, and if needed with the family, health professionals, pharmacy and/or law enforcement personel. And prompt removal of the drug can be lifesaving. Caution: drug withdrawal can produce a flare of the underlying condition for which the drug was exactly given. Deliberate rechallenge can be hazardous as fatal relapse of the respiratiory reaction can supervene. Early sampling of body fluids for drug and/or metabolites is indicated as early as possible, particularly in the severely ill. Knowledge of toxidromes and antidotes capable of countering adverse effects of drugs or chemicals is essential (ex: PMID ). Where in doubt, consider double-checking PubMed, your affiliated Safety for Medicines Department/Agency and the Pharmacovigilance Department of drug companies. They may host more and/or undisclosed information. Patients should be reassured as such incidents are rare oveall. If needed, they are invited to consult with their treating physicians. Monitoring common causal agents (with red digits in stars) for impending toxicity is strongly advised. You may contact Pneumotox anytime through the contact window. ALL RIGHTS RESERVED The current version of Pneumotox website and App were developed by Akyos Communication Dijon France, under the guidance of Philippe Camus MD

Care Central: Bronchiectasis & NTM is a free mobile application developed to support individuals living with bronchiectasis and NTM lung disease, as well as the healthcare professionals who care for them. The app was created to improve disease management, communication, education, support, and overall quality of care for the bronchiectasis and NTM community. Please seek a doctor’s advice in addition to using this app and before making any medical decisions. The app is designed with two separate user experiences, allowing patients and caregivers to access tools tailored to daily disease management, while healthcare providers can utilize clinical resources and evidence-based guidance. This dual-track approach helps ensure that users receive information and features most relevant to their role in care. For patients and caregivers, Care Central provides access to BronchandNTM360social, an interactive online community where individuals affected by bronchiectasis and NTM lung disease can connect with others facing similar challenges. The platform allows users to ask questions, participate in discussions, read blogs, share experiences, and engage with patients, caregivers, advocates, physicians, and healthcare professionals in a supportive environment. The app also includes a wide range of educational resources developed and approved by experts in the field. Users can download practical materials such as the Bronchiectasis Action Plan, NTM Management Tool, Symptom Tracker, Wallet Card, and educational booklets designed to help patients better understand and manage their condition. These resources are intended to encourage informed conversations between patients and providers while promoting proactive disease management. To further support patient education, the app features access to podcasts focused on bronchiectasis and NTM lung disease. These episodes include discussions with healthcare experts, patient advocates, caregivers, and individuals living with these conditions, providing listeners with current information, treatment insights, and practical guidance. In addition, users can explore a large educational video library featuring webinars, presentations, and other content focused on treatment strategies, symptom management, and ongoing research. Another key feature is the Care Center Network, which uses geolocation functionality to help users find nearby centers within the Bronchiectasis and NTM Care Center Network. These specialized centers provide high-quality, expert-driven care focused on properly diagnosing and managing bronchiectasis and NTM lung disease. Users can search by ZIP code, state, or address to identify expert centers closest to them. Healthcare professionals using the app have access to clinical tools and evidence-based resources that support patient care and treatment decision-making. Features include a therapy flowchart with updated treatment guidance along with assessment tools such as the Chronic Airways Assessment Test (CAAT) and the modified Medical Research Council (mMRC) breathlessness scale. Providers can also use the app to locate expert centers within the Care Center Network and access downloadable patient education resources to support discussions during clinical visits. In addition to its core features, Care Central connects users directly to other Bronchiectasis and NTM Association resources, including information about actively recruiting clinical trials and relevant clinical publications. By combining patient support, provider tools, educational content, and access to expert care resources in one centralized platform, the app serves as a comprehensive digital resource for the bronchiectasis and NTM community. Care Central: Bronchiectasis & NTM reflects the Bronchiectasis and NTM Association’s commitment to improving awareness, education, collaboration, and quality of care for individuals affected by these chronic lung diseases.